Gonorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, “Gonorrhea Therapeutics Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Gonorrhea Therapeutics market. The report identifies the key trends shaping and driving the global Gonorrhea Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gonorrhea Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Gonorrhea Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gonorrhea Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Gonorrhea Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gonorrhea Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Gonorrhea Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Gonorrhea Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Gonorrhea Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Gonorrhea Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Gonorrhea - Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Etiology 7
2.4 Pathophysiology 7
2.5 Signs and Symptoms 8
2.5.1 Signs and Symptoms in Females 8
2.5.2 Signs and Symptoms in Males 9
2.6 Commonly Used Diagnostic Tests 9
2.7 Treatment and Management Options for Gonorrhea 9
2.8 Prognosis 11
2.9 GlobalData Pipeline Report Guidance 11

3 Gonorrhea Therapeutics - Market Characterization 12
3.1 Gonorrhea Therapeutics Market Size (2006-2011) - Global 12
3.2 Gonorrhea Therapeutics Market Forecast (2011-2019) - Global 13
3.3 Gonorrhea Therapeutics Market Size (2006-2011) - The US 14
3.4 Gonorrhea Therapeutics Market Forecast (2011-2019) - The US 15
3.5 Gonorrhea Therapeutics Market Size (2006-2011) - France 16
3.6 Gonorrhea Therapeutics Market Forecast (2011-2019) - France 17
3.7 Gonorrhea Therapeutics Market Size (2006-2011) - Germany 18
3.8 Gonorrhea Therapeutics Market Forecast (2011-2019) - Germany 19
3.9 Gonorrhea Therapeutics Market Size (2006-2011) - Italy 20
3.10 Gonorrhea Therapeutics Market Forecast (2011-2019) - Italy 21
3.11 Gonorrhea Therapeutics Market Size (2006-2011) - Spain 22
3.12 Gonorrhea Therapeutics Market Forecast (2011-2019) - Spain 23
3.13 Gonorrhea Therapeutics Market Size (2006-2011) - The UK 24
3.14 Gonorrhea Therapeutics Market Forecast (2011-2019) - The UK 25
3.15 Gonorrhea Therapeutics Market Size (2006-2011) - Japan 26
3.16 Gonorrhea Therapeutics Market Forecast (2011-2019) - Japan 27
3.17 Drivers and Barriers for the Gonorrhea Market 28
3.17.1 Gonorrhea Therapeutics Market Drivers 28
3.17.2 Gonorrhea Therapeutics Market Barriers 28
3.18 Opportunity and Unmet Need 29

4 Gonorrhea Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile Marketed Products in the Gonorrhea Therapeutics Market 32
4.3.1 Cephalosporins 32
4.3.2 Cefixime 32
4.3.3 Ceftriaxone 33
4.3.4 Doxycycline 33
4.3.5 Azithromycin 34
4.4 Key Takeaway 34

5 Gonorrhea Therapeutics - Pipeline Assessment 35

6 Gonorrhea Therapeutics - Clinical Trials Mapping 36
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 36
6.2 Clinical Trials by Phase of Clinical Development 36
6.3 Clinical Trials by Trial Status 37
6.4 Clinical Trial by Prominent Sponsors 38
6.5 Clinical Trials by Overall Sponsors 39
6.6 Company Participating in Gonorrhea Therapeutics Clinical Trials 39

7 Gonorrhea Therapeutics - Strategic Assessment 40
7.1 Key Events Impacting the Future Market 40
7.2 Future Market Competition Scenario 41

8 Gonorrhea Therapeutics - Licensing & Partnership Deals 42

9 Gonorrhea Therapeutics - Appendix 43
9.1 Market Definitions 43
9.2 Acronyms 43
9.3 Research Methodology 43
9.3.1 Coverage 44
9.3.2 Secondary Research 44
9.3.3 Forecasting 44
9.3.4 Primary Research 46
9.3.5 Expert Panel Validation 47
9.4 Contact Us 47
9.5 Disclaimer 47
9.6 Bibliography 48

List of Tables

Table 1: Incidence of Gonorrhea 7
Table 2: Treatments Regimens for Gonococcal Infection and Associated Conditions 10
Table 3: Treatments Regimens for Pelvic Inflammatory Disease (PID) 10
Table 4: Gonorrhea Therapeutics Market, Global, Revenue ($m), 2006–2011 12
Table 5: Gonorrhea Therapeutics, Market, Global, Forecast ($m), 2011–2019 13
Table 6: Gonorrhea Therapeutics Market, The US, Revenue ($m), 2006–2011 14
Table 7: Gonorrhea Therapeutics Market, The US, Forecasts ($m), 2011–2019 15
Table 8: Gonorrhea Therapeutics Market, France, Revenue ($’000), 2006–2011 16
Table 9: Gonorrhea Therapeutics Market, France, Forecasts ($’000), 2011–2019 17
Table 10: Gonorrhea Therapeutics Market, Germany, Revenue ($’000), 2006–2011 18
Table 11: Gonorrhea Therapeutics Market, Germany, Forecasts ($’000), 2011–2019 19
Table 12: Gonorrhea Therapeutics Market, Italy, Revenue ($’000), 2006–2011 20
Table 13: Gonorrhea Therapeutics Market, Italy, Forecasts ($’000), 2011–2019 21
Table 14: Gonorrhea Therapeutics Market, Spain, Revenue ($’000), 2006–2011 22
Table 15: Gonorrhea Therapeutics Market, Spain, Forecasts ($’000), 2011–2019 23
Table 16: Gonorrhea Therapeutics Market, The UK, Revenue ($’000), 2006–2011 24
Table 17: Gonorrhea Therapeutics Market, The UK, Forecasts ($’000), 2011–2019 25
Table 18: Gonorrhea Therapeutics Market, Japan, Revenue ($’000), 2006–2011 26
Table 19: Gonorrhea Therapeutics Market, Japan, Forecasts ($’000), 2011–2019 27
Table 20: Gonorrhea Therapeutics – Clinical Trials by Country, 2011 36
Table 21: Gonorrhea Therapeutics, Major Markets – Clinical Trials by Phase, 2011 37
Table 22: Gonorrhea Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 37
Table 23: Gonorrhea Therapeutics – Prominent Sponsors, 2011 38
Table 24: Gonorrhea Therapeutics – Overall Sponsors, 2011 39
Table 25: Gonorrhea Therapeutics, Global, Deals 42

List of Figures

Figure 1: Gonorrhea Therapeutics Market, Global, Revenue ($m), 2006–2011 12
Figure 2: Gonorrhea Therapeutics Market, Global, Forecast ($m), 2011–2019 13
Figure 3: Gonorrhea Therapeutics Market, The US, Revenue ($m), 2006–2011 14
Figure 4: Gonorrhea Therapeutics Market, The US, Forecast ($m), 2011–2019 15
Figure 5: Gonorrhea Therapeutics Market, France, Revenue ($’000), 2006–2011 16
Figure 6: Gonorrhea Therapeutics Market, France, Forecast ($’000), 2011–2019 17
Figure 7: Gonorrhea Therapeutics Market, Germany, Revenue ($’000), 2006–2011 18
Figure 8: Gonorrhea Therapeutics Market, Germany, Forecast ($’000), 2011–2019 19
Figure 9: Gonorrhea Therapeutics Market, Italy, Revenue ($’000), 2006–2011 20
Figure 10: Gonorrhea Therapeutics Market, Italy, Forecast ($’000), 2011–2019 21
Figure 11: Gonorrhea Therapeutics Market, Spain, Revenue ($’000), 2006–2011 22
Figure 12: Gonorrhea Therapeutics Market, Spain, Forecast ($’000), 2011–2019 23
Figure 13: Gonorrhea Therapeutics Market, The UK, Revenue ($’000), 2006–2011 24
Figure 14: Gonorrhea Therapeutics Market, The UK, Forecast ($’000), 2011–2019 25
Figure 15: Gonorrhea Therapeutics Market, Japan, Revenue ($’000), 2006–2011 26
Figure 16: Gonorrhea Therapeutics Market, Japan, Forecast ($’000), 2011–2019 27
Figure 17: Opportunity and Unmet Need in the Gonorrhea Therapeutics Market 29
Figure 18: Strategic Competitor Assessment, 2011 31
Figure 19: Gonorrhea Therapeutics, Major Markets – Clinical Trials by Phase, 2011 36
Figure 20: Gonorrhea Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 37
Figure 21: Gonorrhea Therapeutics, Major Markets, Overall Sponsors, 2011 38
Figure 22: Gonorrhea Therapeutics, Major Markets, Prominent Sponsors, 2011 39
Figure 23: Gonorrhea Therapeutics Market, Drivers and Restraints 2011 40
Figure 24: Implications for Future Market Competition in the Gonorrhea Therapeutics Market, 2011 41
Figure 25: GlobalData Market Forecasting Model 46